Impact of new generation hormono-therapy on cognitive functions in elderly patients treated for a metastatic prostate cancer

Trial Profile

Impact of new generation hormono-therapy on cognitive functions in elderly patients treated for a metastatic prostate cancer

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 22 Sep 2017

At a glance

  • Drugs Abiraterone acetate (Primary) ; Enzalutamide (Primary)
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Acronyms COG-PRO
  • Most Recent Events

    • 02 Dec 2016 Planned End Date changed from 20 Jul 2018 to 1 Nov 2019.
    • 13 Oct 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top